The techniques of endovascular treatment for arteriosclerotic occlusive disease of lower limbs have developed rapidly in recent years. With the concern of restenosis after the traditional balloon dilatation and metal bare stent implantation looming large, various kinds of drug-carrying apparatus have been developed, and the drug eluting stent (DES) is a typical one among them. DES has been widely used in the treatment of femoropopliteal and below-the-knee arterial diseases, and relative clinical trials have also been widely conducted. The safety, efficacy and superiority of DES in treatment of short-segment lesions have been well demonstrated, while its value in treating long-segment lesions still needs to be verified by further clinical trials.